Zoetis Inc. (NYSE:ZTS) Shares Acquired by Ayrshire Capital Management LLC

Ayrshire Capital Management LLC grew its position in Zoetis Inc. (NYSE:ZTS) by 2.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,339 shares of the company’s stock after purchasing an additional 830 shares during the quarter. Zoetis makes up 2.9% of Ayrshire Capital Management LLC’s investment portfolio, making the stock its 19th largest position. Ayrshire Capital Management LLC’s holdings in Zoetis were worth $6,123,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Webster Bank N. A. raised its stake in Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in Zoetis during the 4th quarter worth $40,000. Quarry LP raised its stake in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares in the last quarter. LRI Investments LLC acquired a new stake in Zoetis during the 1st quarter worth $43,000. Finally, Ables Iannone Moore & Associates Inc. acquired a new stake in Zoetis during the 4th quarter worth $51,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 0.1 %

Shares of NYSE:ZTS opened at $190.08 on Friday. The company has a market cap of $86.12 billion, a price-to-earnings ratio of 37.20, a PEG ratio of 2.95 and a beta of 0.89. The firm’s 50-day simple moving average is $188.07 and its 200-day simple moving average is $176.20. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.41 earnings per share. As a group, equities research analysts predict that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio is currently 33.86%.

Analysts Set New Price Targets

Several brokerages recently commented on ZTS. BTIG Research lifted their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Piper Sandler raised their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. JPMorgan Chase & Co. raised their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Stifel Nicolaus raised their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.